<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(FINAL AMENDMENT )*
CELL THERAPEUTICS, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
150934 10 7
(CUSIP Number)
James J. Bergin, Esq.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
(723) 524-2383
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
February 28, 2000
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box.
[ ]
NOTE: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are
to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 9 Pages
<PAGE> 2
SCHEDULE 13D
- --------------------------------- -------------------------------
CUSIP NO. 150934 10 7 PAGE 2 OF 9 PAGES
- --------------------------------- -------------------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Johnson & Johnson 22-1024240
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
[ ]
(b)
[ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
- -------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH
REPORTING
PERSON
WITH
---------------------------------------------------------------
8 SHARED VOTING POWER
95,762
---------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
95,762
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
95,762
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
.55%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 3
SCHEDULE 13D
- --------------------------------- -------------------------------
CUSIP NO. 150934 10 7 PAGE 3 OF 9 PAGES
- --------------------------------- -------------------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Johnson & Johnson Development Corporation 22-2007137
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
[ ]
(b)
[ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
- -------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH
REPORTING
PERSON
WITH
---------------------------------------------------------------
8 SHARED VOTING POWER
95,762
---------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
95,762
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
95,762
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
.55%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 4
CUSIP 150934 10 7 Page 4 of 9 Pages
Final Amendment to Schedule 13D
This Statement amends Items 2 and 5 of the Statement on Schedule 13D (the
"Schedule 13D") relating to the shares of Common Stock, no par value, of Cell
Therapeutics, Inc., a Washington corporation (the "Company") originally filed
with the Securities and Exchange Commission on November 6, 1997 by Johnson &
Johnson ("J&J") and Johnson & Johnson Development Corporation ("JJDC"), both New
Jersey corporations. Capitalized terms used but not otherwise defined herein
have the same meaning as in the Schedule 13D.
Item 2. Identity and Background
Item 2 is hereby amended by deleting the information in Schedule A
attached to the Schedule 13D and substituting in lieu the Schedule A
attached hereto. Schedule A sets forth the name, business address,
citizenship and present principal occupation of each of the officers
and directors of J&J and JJDC.
Item 5. Interest in Securities of the Issuer:
Item 5 is hereby amended by deleting the information in Item 5 of
the Schedule 13D and substituting in lieu the information below.
(a) As of the date hereof, J&J and JJDC each had beneficial
ownership of an aggregate 95,762 shares of Common Stock, which
constituted approximately .55% of the outstanding shares of
Common Stock of the Company at that time. The percentage
amount set forth above is based upon the number of shares of
Common Stock issued and outstanding as of November 15, 1999,
as reported in the Company's Quarterly Report on Form 10-Q for
the quarter ended September 30, 1999, and as adjusted by the
Company's report on Form 8-K dated January 25, 2000
(b) J&J and JJDC each have shared power to vote and shared power
to dispose of all shares described in paragraph (a) above.
(c) There were no transactions in the Common Stock of the Company
effected by J&J during the past sixty days. Set forth below is
a list of the transactions in the Common Stock of the Company
effected by JJDC during the last sixty days:
<PAGE> 5
CUSIP 150934 10 7 Page 5 of 9 Pages
<TABLE>
<CAPTION>
Amount of
Date of Securities Price per Acquired or (A) Where and How
Transaction Involved Share Disposed (D) Transaction Effected
<S> <C> <C> <C> <C>
2/28/00 215,000 $31.30 (D) Over the Counter
through a broker
2/29/00 250,000 $35.98 (D) Over the Counter
through a broker
3/01/00 235,000 $44.38 (D) Over the Counter
through a broker
3/02/00 72,500 $42.62 (D) Over the Counter
through a broker
</TABLE>
To the best knowledge of J&J and JJDC, no director or
executive officer of J&J or JJDC beneficially owns any shares
of Common Stock or other securities of the Company. Neither
J&J nor JJDC is aware of any other transaction in such
securities during the past sixty (60) days by any of its
executive officers or directors.
(d) Not applicable.
(e) The Reporting Person ceased to be the owner of more than five
percent (5%) of the Common Stock on January 13, 2000. On that
day the Company completed its acquisition of PolaRx
Biopharmaceuticals Inc. in consideration of which the Company
issued 2 million additional shares of Common Stock to the
shareholders of PolaRx. As a result of this additional
issuance, the percentage of Common Stock held by the Reporting
Person was reduced to four point nine two percent (4.92%) of
the outstanding Common Stock. The percentage amount set forth
above is based upon the number of shares of Common Stock
issued and outstanding as of November 15, 1999, as reported in
the Company's Quarterly Report on Form 10-Q for the quarter
ended September 30, 1999 as adjusted by the Company's report
on Form 8-K dated January 25, 2000. This is a final amendment
to the Schedule 13D.
<PAGE> 6
CUSIP 150934 10 7 Page 6 of 9 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete and
correct.
JOHNSON & JOHNSON
Dated: March 8, 2000 By /s/ M. Ullmann
-----------------------------
Name: Michael Ullmann
Title: Secretary
JOHNSON & JOHNSON DEVELOPMENT
CORPORATION
Dated: March 8, 2000 By /s/ E. B. Jung
-----------------------------
Name: Eric B. Jung
Title: Secretary
<PAGE> 7
CUSIP 150934 10 7 Page 7 of 9 Pages
SCHEDULE A
Board of Directors and Executive Officers of
Johnson & Johnson
The directors and executive officers of Johnson & Johnson are identified
in the table below. Directors of Johnson & Johnson are indicated by an asterisk.
<TABLE>
<CAPTION>
Name Business Address Citizenship Principal Occupation
- ---- ---------------- ----------- --------------------
<S> <C> <C> <C>
1. Gerard N. Burrow M.D.(*) Yale New Haven School of Medicine United States Special Adisor to the President of
333 Cedar Street Yale University for Health Affairs
New Haven, CT 06510
2. Joan Ganz Cooney (*) Children's Television Workshop United States Chairman, Children's Television
One Lincoln Plaza Workshop
New York, NY 10023
3. James G. Cullen (*) Bell Atlantic Corporation United States President and Chief Operating
1310 North Court House Road Officer, Bell Atlantic Corporation
Arlington, VA 22201
4. Robert J. Darretta Johnson & Johnson United States Vice President, Finance and
One Johnson & Johnson Plaza Member, Executive Committee of
New Brunswick, NJ 08933 Johnson & Johnson
5. Russell C. Deyo Johnson & Johnson United States Vice President, Administration,
One Johnson & Johnson Plaza and Member, Executive Committee of
New Brunswick, NJ 08933 Johnson & Johnson
6. Roger S. Fine Johnson & Johnson United States Vice President and General Counsel
One Johnson & Johnson Plaza and Member, Executive Committee of
New Brunswick, NJ 08933 Johnson & Johnson
7. M. Judah Folkman, M.D.(*) Children's Hospital United States Senior Associate in Surgery and
Harvard Medical School Director at Children's Hospital
Boston, Ma and Professor of Cell Biology at
Harvard Medical School
8. JoAnn H. Heisen Johnson & Johnson United States Corporate Vice President, Chief
One Johnson & Johnson Plaza Information Officer, and Member,
New Brunswick, NJ 08933 Executive Committee of Johnson &
Johnson
9. Ann Dibble Jordan (*) Johnson & Johnson United States Former Director of the Social
One Johnson & Johnson Plaza Services Department, Chicago
New Brunswick, NJ 08933 Lying-In Hospital
10. Christian A. Koffmann Johnson & Johnson France Member, Executive Committee of
One Johnson & Johnson Plaza Johnson & Johnson
New Brunswick, NJ 08933
</TABLE>
<PAGE> 8
CUSIP 150934 10 7 Page 8 of 9 Pages
<TABLE>
<CAPTION>
Name Business Address Citizenship Principal Occupation
- ---- ---------------- ----------- --------------------
<S> <C> <C> <C>
11. Arnold G. Langbo (*) 111 Capital Avenue, S.W. Canada Chairman of the Board of the
Battle Creek, MI 49015 Kellogg Company
12. Ralph S. Larsen (*) Johnson & Johnson United States Chairman, Board of Directors,
One Johnson & Johnson Plaza Chief Executive Officer and
New Brunswick, NJ 08933 Chairman, Executive Committee, of
Johnson & Johnson
13. James T. Lenehan Johnson & Johnson United States Member, Executive Committee of
One Johnson & Johnson Plaza Johnson & Johnson
New Brunswick, NJ 08933
14. John S. Mayo Ph.D.(*) AT&T Bell Laboratories, Inc. United States President, Emeritus, AT&T Bell
600 Mountain Avenue Laboratories, Inc.
Murray Hill, NJ 07974
15. Leo F. Mullin (*) Delta Airlines, Inc. United States Chairman and Chief Executive
Officer of Delta Airlines, Inc.
16. Brian D. Perkins Johnson & Johnson United States Member, Executive Committee of
One Johnson & Johnson Plaza Johnson & Johnson
New Brunswick, NJ 08933
17. Paul J. Rizzo (*) IBM Corporation United States Retired Vice Chairman of
Old Orchard Road International Business Machines
Armonk, NY 10504 Corporation
18. Henry B. Schact (*) Lucent Technologies United States Former Chairman and Chief
600 Mountain Avenue Executive Officer of Lucent
Murray Hill, N.J. 07974 Technologies
19. Maxine F. Singer, Ph.D.(*) Carnegie Institution of United States President of the Carnegie
Washington Institution of Washington
1530 P Street, N.W.
Washington, D.C. 20005-1910
20. John W. Snow (*) CSX Corporation United States Chairman, President and Chief
Executive Officer of CSX
Corporation
21. Robert N. Wilson (*) Johnson & Johnson United States Vice Chairman, Board of Directors
One Johnson & Johnson Plaza and Vice Chairman, Executive
New Brunswick, NJ 08933 Committee of Johnson & Johnson
</TABLE>
<PAGE> 9
CUSIP 150934 10 7 Page 9 of 9 Pages
Board of Directors and Executive Officers of
Johnson & Johnson Development Corporation
The directors and executive officers of Johnson & Johnson Development
Corporation are identified in the table below. Directors of Johnson & Johnson
Development Corporation are indicated by an asterisk.
<TABLE>
<CAPTION>
Name Business Address Citizenship Principal Occupation
<S> <C> <C> <C>
1. James R. Utaski(*) Johnson & Johnson United States Vice President of Johnson & Johnson and
One Johnson & Johnson Plaza Chairman of
New Brunswick, NJ 08933 Johnson & Johnson Development
Corporation
2. Larry G. Pickering(*) Johnson & Johnson United States President of
One Johnson & Johnson Plaza Johnson & Johnson Development Corporation
New Brunswick, NJ 08933
3. James R. Hilton (*) Johnson & Johnson United States Associate General Counsel of Johnson &
One Johnson & Johnson Plaza Johnson; and Assistant Secretary of Johnson &
New Brunswick, NJ 08933 Johnson Development Corporation
4. Eric B. Jung (*) Johnson & Johnson United States Assistant Secretary of Johnson & Johnson; and
One Johnson & Johnson Plaza Secretary of Johnson & Johnson Development
New Brunswick, NJ 08933 Corporation
5. Roy Cosan Johnson & Johnson United States Vice President of Johnson & Johnson
One Johnson & Johnson Plaza Development Corporation
New Brunswick, NJ 08933
6. Susan Lambert Johnson & Johnson United Vice President of
One Johnson & Johnson Plaza Kingdom Johnson & Johnson Development
New Brunswick, NJ 08933 Corporation
7. Ting Pau Oei Johnson & Johnson United States Vice President of
One Johnson & Johnson Plaza Johnson & Johnson Development Corporation
New Brunswick, NJ 08933
8. Brad Vale, D.V.M. Johnson & Johnson United States Vice President of
One Johnson & Johnson Plaza Johnson & Johnson Development Corporation
New Brunswick, NJ 08933
9. Z. Zehavi Johnson & Johnson United States Vice President of
One Johnson & Johnson Plaza Johnson & Johnson Development Corporation
New Brunswick, NJ 08933
</TABLE>
